Structure Therapeutics Executive Compensation (FY25)
GPCR · Executive and director compensation, fiscal 2025 only
The Structure Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): June 18, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
180 figures on this page: 178 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Structure Therapeutics' chief executive and what were they paid?
Raymond Stevens was paid $8,429,887 in total compensation as Chief Executive Officer and Director for fiscal 2025.
What was Structure Therapeutics' say-on-pay result?
The say-on-pay proposal drew 96.2% of votes cast for or against in favor at the meeting held June 17, 2026 for fiscal 2025.
What is Structure Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 29:1 for fiscal 2025, against median employee compensation of $293,807.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Raymond Stevens Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jun Yoon Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Blai Coll Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Xichen Lin Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Yingli Ma Chief Technology Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Blai Coll | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Blai Coll | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jun Yoon | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jun Yoon | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Raymond Stevens | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Raymond Stevens | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Xichen Lin | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Xichen Lin | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Yingli Ma | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Yingli Ma | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jun Yoon | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | 9/22/2031 | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Raymond Stevens | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Yingli Ma | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | 1/19/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Xichen Lin | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | 9/22/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Jun Yoon
Chief Financial Officer · Amended agreement
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Daniel G. Welch Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Sharon Tetlow | ◇ | — | ◇ | — | — | — | ◇ |
Ted W. Love, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Joanne Waldstreicher, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Eric Dobmeier | ◇ | — | ◇ | — | — | — | ◇ |
Angus C. Russell | ◇ | — | ◇ | — | — | — | ◇ |
Raymond Stevens, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Element ESI
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 17, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 23, 2025 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Structure Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Structure Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
180 figures on this page: 178 cited to the filing that reported them, 2 calculated from figures it prints.
178 cited to the filing
2 calculated from the filing
Documents cited
- 0001104659-26-075720
- 0001104659-26-047740CEO Pay Ratio · Grants of Plan-Based Awards · NON-EMPLOYEE DIRECTOR COMPENSATION · Outstanding Equity Awards at 2025 Fiscal Year-End Table · and 1 more section
- 0001104659-25-062576Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-23-003415Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Structure Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/GPCR (accessed 2026).
Short form: data: Velarion
The Structure Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Structure Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Structure Therapeutics discloses
The companies named in GPCR's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}